NTLA · Intellia Therapeutics, Inc.
Intellia Therapeutics (NTLA) is a clinical-stage CRISPR gene-editing company advancing systemically administered in vivo programs into late-stage trials. The company reported its Form 10-Q for the quarter ended March 31, 2026; financials show continuing investment in R&D, a net loss for the quarter, and a cash and marketable securities position intended to fund operations for at least the next 12 months. Recent market moves appear driven by broader positioning rather than a single company catalyst.
Recent proof-backed thesis calls
Latest published recommendation: sell. Rationale cites the NTLA 10-Q for the quarter ended 2026-03-31 as the primary input (moderate confidence) and notes a thematic, long-horizon beneficiary thesis for platforms addressing aging-related gene-expression drift (low confidence).
A social post claims California is about to pass a bill banning “aesthetic” gene editing in pets and that the bill cites the author’s company; it frames this as regulation of technology (methods) rather than outcomes. No bill number, timing, or details are provided, so tradability is limited without verification.
The source is a one-line conceptual statement about aging as a drift from optimal gene expression. It provides no company, product, catalyst, timing, or investable details, so it is not directly actionable for trading without additional context (e.g., specific targets, modalities, clinical readouts, or firms).
This excerpt of NTLA’s 10‑Q (quarter ended 2026‑03‑31) contains only the SEC cover page/filing status and listing information, with no financial statements, guidance, program updates, risks, cash runway, or material events. It is therefore not actionable for trading on fundamentals.
ARK’s Big Ideas 2026 (Multiomics) segment outlines the investment case for “multiomics” (integrating genomics, transcriptomics, proteomics, etc.) as biology moves from single-layer measurement to multi-layer data + computation. The talk highlights downstream implications across (1) data generation (sequencing/single-cell/proteomics platforms), (2) diagnostics (earlier, cheaper, more precise testing), (3) drug development (better target ID/stratification), and (4) therapeutics (more precise, pote
Latest market-close explanation
On 2026-06-01 NTLA closed down 2.42% at $13.73 on lower volume. Intraday range was $13.41–$14.17. No company-specific catalyst was identified; the move likely reflects market/sector dynamics.
No market-close explanation is available for `NTLA` on 2026-07-24 because usable price history was not available. Reason: no_market_data.
Current stance
Sell — recommendation driven by the recent 10-Q disclosures and near-term financial and operating readouts; conviction tempered by thematic upside for gene‑editing platforms over the long term.
- sell via NTLA 10-Q report for 2026-03-31 from https://www.sec.gov/edgar/search/ (confidence 0.60)
- risk via Regulatory headline risk for gene-editing platforms (low-conviction, needs verification) from https://x.com/webuildlife (confidence 0.20)
- beneficiary via Longevity/aging-as-gene-expression-drift is a long-horizon narrative tailwind for gene-expression measurement and modulation platforms. from https://x.com/davidasinclair (confidence 0.17)
Top authors on this asset
Active and historical ticker theses
Active research themes include: (1) the company’s Form 10-Q (2026-03-31) reporting quarter-to-date financials, cash runway commentary, and program updates; (2) a thematic, long-horizon narrative that aging represents gene-expression drift, which could benefit gene-expression measurement and modulation platforms.
NTLA 10-Q report for 2026-03-31
Regulatory headline risk for gene-editing platforms (low-conviction, needs verification)
Longevity/aging-as-gene-expression-drift is a long-horizon narrative tailwind for gene-expression measurement and modulation platforms.
Unlock full asset monitoring
Review NTLA’s full 10-Q at the SEC EDGAR site for detailed financials and MD&A. For traders, consider position sizing consistent with the sell recommendation and monitor upcoming clinical and commercial milestones (e.g., Phase 3 program updates and 2027 planned launch preparations).